Literature DB >> 25802333

Induction of heme oxygenase-1 by Na+-H+ exchanger 1 protein plays a crucial role in imatinib-resistant chronic myeloid leukemia cells.

Dan Ma1, Qin Fang2, Ping Wang3, Rui Gao3, Weibing Wu3, Tangsheng Lu4, Lu Cao4, Xiuying Hu3, Jishi Wang5.   

Abstract

Resistance toward imatinib (IM) and other BCR/ABL tyrosine kinase inhibitors remains troublesome in the treatment of advanced stage chronic myeloid leukemia (CML). The aim of this study was to estimate the reversal effects of down-regulation of Na(+)/H(+) exchanger 1 (NHE1) on the chemoresistance of BCR-ABL-positive leukemia patients' cells and cell lines. After treatment with the specific NHE1 inhibitor cariporide to decrease intracellular pH (pHi), the heme oxygenase-1 (HO-1) levels of the K562R cell line and cells from IM-insensitive CML patients decreased. HO-1, as a Bcr/Abl-dependent survival molecule in CML cells, is important for the resistance to tyrosine kinase inhibitors in patients with newly diagnosed CML or IM-resistant CML. Silencing PKC-β and Nrf-2 or treatment with inhibitors of p38 pathways obviously blocked NHE1-induced HO-1 expression. Furthermore, treatment with HO-1 or p38 inhibitor plus IM increased the apoptosis of the K562R cell line and IM-insensitive CML patients' cells. Inhibiting HO-1 enhanced the activation of caspase-3 and poly(ADP-ribose) polymerase-1. Hence, the results support the anti-apoptotic role of HO-1 induced by NHE1 in the K562R cell line and IM-insensitive CML patients and provide a mechanism by which inducing HO-1 expression via the PKC-β/p38-MAPK pathway may promote tumor resistance to oxidative stress.
© 2015 by The American Society for Biochemistry and Molecular Biology, Inc.

Entities:  

Keywords:  Na+/H+ ion exchanger 1; chronic myelogenous leukemia (CML); drug resistance; heme oxygenase; imatinib resistance; p38 MAPK; p38/mitogen-activated protein kinase; protein kinase C (PKC)

Mesh:

Substances:

Year:  2015        PMID: 25802333      PMCID: PMC4432277          DOI: 10.1074/jbc.M114.626960

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  44 in total

1.  Bcr-Abl-mediated molecular mechanism for apoptotic suppression in multipotent haemopoietic cells: a role for PKCbetaII.

Authors:  Dia Xenaki; Andrew Pierce; Nick Underhill-Day; Anthony D Whetton; P Jane Owen-Lynch
Journal:  Cell Signal       Date:  2004-02       Impact factor: 4.315

2.  HS-438, a new inhibitor of imatinib-resistant BCR-ABL T315I mutation in chronic myeloid leukemia.

Authors:  Sun-Mi Yun; Kyung Hee Jung; Soo Jung Kim; Zhenghuan Fang; Mi Kwon Son; Hong Hua Yan; Hyunseung Lee; JinHee Kim; Sanghye Shin; Sungwoo Hong; Soon-Sun Hong
Journal:  Cancer Lett       Date:  2014-03-18       Impact factor: 8.679

3.  BCR-ABL kinase domain mutations, including 2 novel mutations in imatinib resistant Malaysian chronic myeloid leukemia patients-Frequency and clinical outcome.

Authors:  Marjanu Hikmah Elias; Abdul Aziz Baba; Husin Azlan; Hassan Rosline; Goh Ai Sim; Menon Padmini; S Abdul Wahid Fadilah; Ravindran Ankathil
Journal:  Leuk Res       Date:  2014-01-06       Impact factor: 3.156

4.  Comprehensive therapeutic outcomes of frontline imatinib mesylate in newly diagnosed chronic phase chronic myeloid leukemia patients in Korea: feasibility assessment of current ELN recommendation.

Authors:  Dongho Kim; Hyun Gyung Goh; Soo-Hyun Kim; Soo-Young Choi; Sa-Hee Park; Eun-Jung Jang; Dong-Wook Kim
Journal:  Int J Hematol       Date:  2012-05-19       Impact factor: 2.490

5.  Cardioprotective and antiapoptotic effects of heme oxygenase-1 in the failing heart.

Authors:  Guangwu Wang; Tariq Hamid; Rachel J Keith; Guihua Zhou; Charles R Partridge; Xilin Xiang; Justin R Kingery; Robert K Lewis; Qianhong Li; D Gregg Rokosh; Rachael Ford; Francis G Spinale; Daniel W Riggs; Sanjay Srivastava; Aruni Bhatnagar; Roberto Bolli; Sumanth D Prabhu
Journal:  Circulation       Date:  2010-04-19       Impact factor: 29.690

6.  Nuclear translocation of heme oxygenase-1 confers resistance to imatinib in chronic myeloid leukemia cells.

Authors:  Daniele Tibullo; Ignazio Barbagallo; Cesarina Giallongo; Piera La Cava; Nunziatina Parrinello; Luca Vanella; Fabio Stagno; Giuseppe A Palumbo; Giovanni Li Volti; Francesco Di Raimondo
Journal:  Curr Pharm Des       Date:  2013       Impact factor: 3.116

7.  The coffee diterpene kahweol induces heme oxygenase-1 via the PI3K and p38/Nrf2 pathway to protect human dopaminergic neurons from 6-hydroxydopamine-derived oxidative stress.

Authors:  Yong Pil Hwang; Hye Gwang Jeong
Journal:  FEBS Lett       Date:  2008-06-30       Impact factor: 4.124

8.  Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl.

Authors:  Ellen Weisberg; Paul W Manley; Werner Breitenstein; Josef Brüggen; Sandra W Cowan-Jacob; Arghya Ray; Brian Huntly; Doriano Fabbro; Gabriele Fendrich; Elizabeth Hall-Meyers; Andrew L Kung; Jürgen Mestan; George Q Daley; Linda Callahan; Laurie Catley; Cara Cavazza; Mohammad Azam; Azam Mohammed; Donna Neuberg; Renee D Wright; D Gary Gilliland; James D Griffin
Journal:  Cancer Cell       Date:  2005-02       Impact factor: 31.743

9.  Carbon monoxide expedites metabolic exhaustion to inhibit tumor growth.

Authors:  Barbara Wegiel; David Gallo; Eva Csizmadia; Clair Harris; John Belcher; Gregory M Vercellotti; Nuno Penacho; Pankaj Seth; Vikas Sukhatme; Asif Ahmed; Pier Paolo Pandolfi; Leszek Helczynski; Anders Bjartell; Jenny Liao Persson; Leo E Otterbein
Journal:  Cancer Res       Date:  2013-10-11       Impact factor: 12.701

Review 10.  Identifying the time to change BCR-ABL inhibitor therapy in patients with chronic myeloid leukemia.

Authors:  Michael R Savona; Giuseppe Saglio
Journal:  Acta Haematol       Date:  2013-08-15       Impact factor: 2.195

View more
  11 in total

1.  Adipose Mesenchymal Stem Cell-Derived Exosomal microRNA-1236 Reduces Resistance of Breast Cancer Cells to Cisplatin by Suppressing SLC9A1 and the Wnt/β-Catenin Signaling.

Authors:  Zhongming Jia; Huamin Zhu; Hongguang Sun; Yitong Hua; Guoqiang Zhang; Jingru Jiang; Xiaohong Wang
Journal:  Cancer Manag Res       Date:  2020-09-22       Impact factor: 3.989

2.  Blocking autophagy enhanced leukemia cell death induced by recombinant human arginase.

Authors:  Yubin Li; Xian Zeng; Shaofei Wang; Jiajun Fan; Ziyu Wang; Ping Song; Xiaobin Mei; Dianwen Ju
Journal:  Tumour Biol       Date:  2015-12-07

Review 3.  The Nrf2/HO-1 Axis in Cancer Cell Growth and Chemoresistance.

Authors:  A L Furfaro; N Traverso; C Domenicotti; S Piras; L Moretta; U M Marinari; M A Pronzato; M Nitti
Journal:  Oxid Med Cell Longev       Date:  2015-11-30       Impact factor: 6.543

4.  Cariporide Enhances the DNA Damage and Apoptosis in Acid-tolerable Malignant Mesothelioma H-2452 Cells.

Authors:  Yoon-Jin Lee; Jin-Ho Bae; Soo-A Kim; Sung-Ho Kim; Kee-Min Woo; Hae-Seon Nam; Moon-Kyun Cho; Sang-Han Lee
Journal:  Mol Cells       Date:  2017-08-10       Impact factor: 5.034

5.  Increased NHE1 expression is targeted by specific inhibitor cariporide to sensitize resistant breast cancer cells to doxorubicin in vitro and in vivo.

Authors:  Qi Chen; Yueqin Liu; Xiao-Lan Zhu; Fan Feng; Hui Yang; Wenlin Xu
Journal:  BMC Cancer       Date:  2019-03-08       Impact factor: 4.430

6.  Genomic and transcriptomic profiling of resistant CEM/ADR-5000 and sensitive CCRF-CEM leukaemia cells for unravelling the full complexity of multi-factorial multidrug resistance.

Authors:  Onat Kadioglu; Jingming Cao; Nadezda Kosyakova; Kristin Mrasek; Thomas Liehr; Thomas Efferth
Journal:  Sci Rep       Date:  2016-11-08       Impact factor: 4.379

7.  Translocation of heme oxygenase-1 contributes to imatinib resistance in chronic myelogenous leukemia.

Authors:  Bianca Schaefer; Soenke Behrends
Journal:  Oncotarget       Date:  2017-06-27

8.  Targeting of heme oxygenase-1 attenuates the negative impact of Ikaros isoform 6 in adult BCR-ABL1-positive B-ALL.

Authors:  Xiaojing Lin; Xingli Zou; Ziming Wang; Qin Fang; Shuya Chen; Jun Huang; Nana Zhe; Meisheng Yu; Yaming Zhang; Jishi Wang
Journal:  Oncotarget       Date:  2016-08-16

9.  Silencing heme oxygenase-1 increases the sensitivity of ABC-DLBCL cells to histone deacetylase inhibitor in vitro and in vivo.

Authors:  Zhen Zhou; Qin Fang; Dan Ma; Nana Zhe; Mei Ren; Bingqing Cheng; Peifan Li; Ping Liu; Xiaojing Lin; Sishi Tang; Xiuying Hu; Yudan Liao; Yaming Zhang; Tingting Lu; Jishi Wang
Journal:  Oncotarget       Date:  2017-07-28

10.  Widespread expression of Sonic hedgehog (Shh) and Nrf2 in patients treated with cisplatin predicts outcome in resected tumors and are potential therapeutic targets for HPV-negative head and neck cancer.

Authors:  Abu Shadat M Noman; Rashed R Parag; Muhammad I Rashid; Mohammad Z Rahman; Ali A Chowdhury; Afrin Sultana; Chandsultana Jerin; Ayesha Siddiqua; Lutfur Rahman; Afsana Shirin; Junayed Nayeem; Reaz Mahmud; Sonam Akther; Rajib K Shil; Ikram Hossain; Sharmin Alam; Arfina Chowdhury; Shabnam B Basher; Abul Hasan; Shammy Bithy; Jannatul Aklima; Mizanur Rahman; Nabila Chowdhury; Tahmina Banu; Bedri Karakas; Herman Yeger; Walid A Farhat; Syed S Islam
Journal:  Ther Adv Med Oncol       Date:  2020-03-13       Impact factor: 8.168

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.